LimmaTech Biologics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 55

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $780M

LimmaTech Biologics General Information

Description

Operator of a clinical-stage biopharmaceutical firm intended to focus on the prevention of life-threatening diseases. The company specializes in the research, development, and manufacture of bioconjugate vaccines using glycoengineering, protein glycosylation, and in vivo enzyme-based method that alleviates the issues associated with the chemical conjugation process and helps in the advancement of vaccines for multiple pathogens, enabling healthcare sectors to develop inoculation efficiently and reducing the time and cost.

Contact Information

Website
www.lmtbio.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Grabenstrasse 3
  • 8952 Schlieren
  • Switzerland
+41 044
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Corporate Office
  • Grabenstrasse 3
  • 8952 Schlieren
  • Switzerland
+41 044

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LimmaTech Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 31-Jul-2026 $780M Completed Clinical Trials - Phase 1
5. Grant 18-Feb-2025 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A) 01-Feb-2024 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator Completed Pre-Clinical Trials
2. Grant 01-Jul-2020 $841K $168K Completed Pre-Clinical Trials
1. Seed Round 01-Oct-2017 $168K $168K Completed Pre-Clinical Trials
To view LimmaTech Biologics’s complete valuation and funding history, request access »

LimmaTech Biologics Patents

LimmaTech Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025239851-A1 Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof Pending 22-Mar-2024
WO-2025196270-A1 Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof Pending 22-Mar-2024
AU-2025207078-A1 Formulations for staphylococcus aureus vaccine Pending 12-Jan-2024
WO-2025149609-A1 Formulations for staphylococcus aureus vaccine Inactive 12-Jan-2024
AU-2021342346-A1 Fab sialylation of antibodies Inactive 14-Sep-2020 C07K16/241
To view LimmaTech Biologics’s complete patent history, request access »

LimmaTech Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LimmaTech Biologics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
AXA Investment Managers Asset Manager Minority
Adjuvant Capital Impact Investing Minority
CARB-X University Minority
INCATE Accelerator/Incubator
Innosuisse Government
You’re viewing 5 of 8 investors. Get the full list »

LimmaTech Biologics FAQs

  • When was LimmaTech Biologics founded?

    LimmaTech Biologics was founded in 2015.

  • Where is LimmaTech Biologics headquartered?

    LimmaTech Biologics is headquartered in Schlieren, Switzerland.

  • What is the size of LimmaTech Biologics?

    LimmaTech Biologics has 55 total employees.

  • What industry is LimmaTech Biologics in?

    LimmaTech Biologics’s primary industry is Biotechnology.

  • Is LimmaTech Biologics a private or public company?

    LimmaTech Biologics is a Private company.

  • What is the current valuation of LimmaTech Biologics?

    The current valuation of LimmaTech Biologics is .

  • What is LimmaTech Biologics’s current revenue?

    The current revenue for LimmaTech Biologics is .

  • How much funding has LimmaTech Biologics raised over time?

    LimmaTech Biologics has raised $40.2M.

  • Who are LimmaTech Biologics’s investors?

    AXA Investment Managers, Adjuvant Capital, CARB-X, INCATE, and Innosuisse are 5 of 8 investors who have invested in LimmaTech Biologics.

  • When was LimmaTech Biologics acquired?

    LimmaTech Biologics was acquired on 31-Jul-2026.

  • Who acquired LimmaTech Biologics?

    LimmaTech Biologics was acquired by Lilly USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process